The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Access to genomic testing, not therapy cost, is the biggest challenge
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The new assay consolidates screening for four major viral threats into a single workflow
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
